Deucravacitinib (Sotyktu®). HTA ID: 23030

Assessment Status Rapid Review Complete
HTA ID 23030
Drug Deucravacitinib
Brand Sotyktu®
Indication Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 01/06/2023
Rapid review completed 27/06/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that deucravacitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations January 2024.